

HIGHLAND HOSPITAL OF ROCHESTER

Directors' Office



Dear Manufacturers,

I am writing on behalf of Highland Hospital of Rochester (340B ID # DSH330164)(“Highland”) to inform manufacturers that Highland recently underwent an audit by the Health Resources and Services Administration (HRSA) of Highland’s compliance with 340B Drug Pricing Program (340B Program) requirements.

As background, Highland qualified for the 340B Program as a Disproportionate Share Hospital most recently in 2013 and has participated in the 340B Program since May 13, 2013.

Through the audit process, Highland was found to have non-compliance within its 340B Program and responsible for repayment as a result of the following finding:

“Highland dispensed 340B drugs to ineligible individuals, as prohibited by section 340B(a)(5)(B) of the PHSA.”

Highland has identified all affected manufacturers and has contacted each to notify them of these findings to begin a dialogue on a method for repayment to affected manufacturers. If manufacturers have not received notification from Highland and believe repayment may be owed for the findings described in this letter, or if you have any questions or comments regarding the findings described in this letter please contact Katy Lees, 340B Business Manager, by phone at (585) 785-5154, or email at katy_lees@urmc.rochester.edu, or by mail at 120 Corporate Woods, Suite 350, Rochester, New York 14623.

Sincerely,

Adam Anolik

Chief Financial Officer